Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Total Current Liabilities (2022 - 2026)

Compass Therapeutics' Total Current Liabilities history spans 5 years, with the latest figure at $10.3 million for Q1 2026.

  • On a quarterly basis, Total Current Liabilities fell 31.01% to $10.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.3 million, a 31.01% decrease, with the full-year FY2025 number at $14.0 million, up 57.4% from a year prior.
  • Total Current Liabilities hit $10.3 million in Q1 2026 for Compass Therapeutics, down from $14.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CMPX hit a ceiling of $16.2 million in Q4 2022 and a floor of $3.9 million in Q1 2024.
  • Historically, Total Current Liabilities has averaged $10.4 million across 5 years, with a median of $10.0 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: tumbled 65.21% in 2024 and later surged 282.74% in 2025.
  • Tracing CMPX's Total Current Liabilities over 5 years: stood at $16.2 million in 2022, then tumbled by 51.75% to $7.8 million in 2023, then rose by 13.75% to $8.9 million in 2024, then skyrocketed by 57.4% to $14.0 million in 2025, then decreased by 26.41% to $10.3 million in 2026.
  • Business Quant data shows Total Current Liabilities for CMPX at $10.3 million in Q1 2026, $14.0 million in Q4 2025, and $12.4 million in Q3 2025.